Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2437-2447

  Cheng, Ting Jen ^a   Brik, Ashraf ^b   Wong, Chi Huey ^b   Kan, Chen Chen ^a  

^a KECK GRADUATE INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMPRENAVIR; BETA GALACTOSIDASE; ENZYME PRECURSOR; INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME ENGINEERING; ENZYME SUBSTRATE; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS; MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SAFETY; VALIDATION PROCESS; VIRUS RESISTANCE; VIRUS STRAIN;

AMIDES; BETA-GALACTOSIDASE; BLOTTING, WESTERN; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS; PLASMIDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3042526692     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2437-2447.2004     Document Type: Article

References (34)

1. Ansaldi, M., M. Lepelletier, and V. Mejean. 1996. Site-specific mutagenesis by using an accurate recombinant polymerase chain reaction method. Anal. Biochem. 234:110-111.
2. Baum, E. Z., G. A. Bebernitz, and Y. Gluzman. 1990. β-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. Proc. Natl. Acad. Sci. USA 87:10023-10027.
3. Brik, A., Y.-C. Lin, J. Elder, and C.-H. Wong. 2002. A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. Chem. Biol. 9:891-896.
4. Brik, A., and C.-H. Wong. 2003. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 1:5-14.
5. Cheng, Y. S. E., F. H. Yin, S. Foundling, D. Blomstrom, and C. A. Kettner. 1990. Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc. Natl. Acad. Sci. USA 87:9660-9664.
6. Dasmahapatra, B., B. DiDomenico, S. Dwyer, J. Ma, I. Sadowski, and J. Schwartz. 1992. A genetic system for studying the activity of a proteolytic enzyme. Proc. Natl. Acad. Sci. USA 89:4159-4162.
7. Dautin, N., G. Karimova, A. Ullmann, and D. Ladant. 2000. A sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli. J. Bacteriol. 182:7060-7066.
8. Erickson, J. W. 2001. HIV-1 protease as a target for AIDS therapy, p. 1-25. In R. C. Ogden and C. W. Flexner (ed.), Protease inhibitors in AIDS therapy. Marcel Dekker, Inc., New York, N.Y.
9. Frankel, A. D., and J. A. Yong. 1998. HIV-1: fifteen proteins and a RNA. Annu. Rev. Biochem. 67:1-25.
10. Gong, Y.-F., B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P.-F. Lin. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:2319-2326.
11. Ishima, R., D. A. Torchia, S. M. Lynch, A. M. Gronenborn, and J. M. Louis. 2003. Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J. Biol. Chem. 278:43311-43319.
12. Kim, S. Y., K. W. Park, Y. J. Lee, S. H. Back, J. H. Goo, O. K. Park, S. K. Jang, and W. J. Park. 2000. In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis. Anal. Biochem. 284:42-48.
13. Klabe, R. M., L. T. Bacheler, P. J. Ala, S. Erickson-Viitanen, and J. L. Meek. 1998. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37:8735-8742.
14. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
15. Krausslich, H. G., R. H. Ingraham, M. T. Skoog, E. Wimmer, P. V. Pallai, and C. A. Carter. 1989. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. USA 86:807-811.
16. Kupiec, J.-J., S. Hazebrouck, T. Leste-Lasserre, and P. Sonigo. 1996. Conversion of thymidylate synthase into an HIV protease substrate. J. Biol. Chem. 271:18465-18470.
17. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
18. gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology 214:624-627.
19. Louis, J. M., C. M. Clore, and A. M. Gronenborn. 1999. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol. 6:868-875.
20. Mahalingam, B., J. M. Louis, J. Hung, R. W. Harrison, and I. T. Weber. 2001. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43:455-464.
21. Mahalingam, B., J. M. Louis, C. C. Reed, J. M. Adomat, J. Krouse, Y.-F. Wang, R. W. Harrison, and I. T. Weber. 1999. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263:238-245.
22. Martínez, M.-A., M. Cabana, M. Parera, A. Gutierrez, J. A. Esté, and B. Clotet. 2000. A bacteriophage lambda genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 44:1132-1139.
23. Pardee, A. B., F. Jacob, and J. Monod. 1959. The genetic control and cytoplasmic expression of inducibility in the synthesis of β-galactosidase of Escherichia coli. J. Mol. Biol. 1:165-168.
24. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
25. Paulus, C., S. Hellebrand, U. Tessmer, H. Wolf, H. G. Krauslich, and R. Wagner. 1999. Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. J. Biol. Chem. 274:21539-21543.
26. Pettit, S. C., S. Gulink, L. Everitt, and A. H. Kaplan. 2003. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol. 77:366-374.
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
28. Schupp, J. M., S. E. Travis, L B. Price, R. F. Shand, and P. Keim. 1995. Rapid bacterial permeabilization reagent useful for enzyme assays. BioTechniques 19:18-20.
29. Sices, H. J., and T. M. Kristie. 1998. A genetic screen for the isolation and characterization of site-specific proteases. Proc. Natl. Acad. Sci. USA 95:2828-2833.
30. Smith, T. A., and B. D. Kohorn. 1991. Direct selection for sequences encoding proteases of known specificity. Proc. Natl. Acad. Sci. USA 88:5159-5162.
31. Tung, R. D., D. J. Livingston, B. G. Rao, E. E. Kim, C. T. Baker, J. S. Boger, S. P. Chambers, D. D. Deininger, M. Dwyer, L. Elsayed, J. Fulghum, B. Li, M. A. Murcko, M. A. Navia, P. Novak, S. Pazhanisamy, C. Stuver, and J. A. Thomson. 2002. Design and synthesis of amprenavir, a novel HIV protease inhibitor. Infect. Dis. Ther. 25:101-118.
32. Wlodawer, A., and J. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-5858.
33. Wondrak, E. M., and J. M. Louis. 1996. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35:12957-12962.
34. Zybarth, G., and C. Carter. 1995. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69:3878-3884.